The technical field generally relates to devices and methods for applying shear stress to live cells (and/or tissue) and in particular microfluidic-based devices for applying shear stress to living cells to induce phenotypic changes and/or enrichment in the cells.
A topic at the forefront of plastic surgery research is addressing the variability experienced when transferring fat from one location to another to fill soft tissue defects (i.e., fat grafting). Cell-assisted lipotransfer (CAL) is a technique used in reconstructive and aesthetic medicine that involves the addition of the stromal vascular fraction (SVF) to fat grafts, and has resulted in significant improvements in fat graft retention. Typically, the SVF is harvested from adipose tissue by a short digestion step using the enzyme collagenase. Recently, a technique called ‘nanofat grafting’ was developed, whereby standard lipoaspirate is homogenized by manually passing it vigorously between two connected syringes, and then reinjecting the homogenized lipoaspirate in human patients for the correction of superficial rhytides and pigmentation. For example, Tonnard et al. disclosed improved skin quality when nanofat was used to correct superficial rhytides, scars, and dark lower eyelids. Tonnard et al., Nanofat grafting: basic research and clinical applications, Plast. Reconstr. Surg., 132(4), pp. 1017-26 (2013). Unfortunately, the current process of generating nanofat is limited by poor control of hydrodynamic shear forces and subject to user-dependent variability which is not ideally suited for clinical environments. Poor control of hydrodynamic shear forces may adversely affect cell viability and the ability to promote shear-stress induced transformation of cells.
According to one embodiment, a method of applying shear stress to live cells involves running live cells (obtained from lipoaspirate) through a microfluidic device having a series of microfluidic channels that include repeating expansion/constriction patterns to induce fluid shear forces on the cells that are passed through the microfluidic channels of the device. In one embodiment, the device contains an inlet, an outlet, and a branching microfluidic channel array located between the inlet and outlet. The branching microfluidic channels include the repeating expansion/constriction patterns. The branching microfluidic channels in the microfluidic device are arranged in a number of serially arranged stages with each stage (in the downstream direction) having an increasing number of channels of reduced dimension. For example, a first stage may include a single microfluidic channel having repeating expansion and constriction regions. This first stage proceeds to a second stage that has multiple microfluidic channels (e.g., two (2)) of reduced dimension (e.g. width) with each having repeating expansion and constriction regions. The second stage then proceeds to a third stage that has multiple microfluidic channels (e.g., four (4)) of reduced dimension (e.g. width) with each having repeating expansion and constriction regions. This third stage then proceeds to a fourth stage that has multiple microfluidic channels (e.g., four (8)) of reduced dimension (e.g. width) with each having repeating expansion and constriction regions. Thus, in this particular embodiment, each stage results in a doubling in the number of microfluidic channels. This doubling in the number of microfluidic channels may be accompanied by a reduction in the width dimension of the microfluidic channel by about one-half. Thus, while each successive stage of the microfluidic device has a doubling in the number of microfluidic channels, each microfluidic channel is reduced in width by half.
Various modifications of the above scheme may be made to the microfluidic device. For example, there may be fewer stages or more stages. Further, rather than have the number of microfluidic channels double after each stage, the number of microfluidic channels may triple, quadruple, or the like. Similarly, at each successive stage, the width does not have to be reduced by half as it could be reduced by some other amount. Further, while the width is described as being reduced, the reduction in dimension of the microfluidic channels in successive stages could include the height as well depending on the orientation of the expansion and constriction regions.
In one particular embodiment, the final or last stage of the device may have a minimum distance within the range of about 200 μm to about 600 μm. The microfluidic channel may have a height that is typically within the range of about 200 to about 500 μm and stays uniform throughout the device. Larger channel dimensions may be used because dissociating the fat tissue all the way down to single cells may damage or even kill the stem cells that we are seeking to stimulate/enrich using the applied mechanical stress.
In one embodiment, an optional filter module is placed directly downstream (or in an alternative embodiment upstream of) of the microfluidic device to filter the processed sample. The filter module may be integrated directly after the microfluidic device for rapid and efficient processing. The filter module may include a nylon filter membrane with pore size of about 500 μm that is sandwiched between layers of PDMS that are patterned using photolithograpy. Other materials such as metal, polymer, cellulose, and the like may be used instead of nylon. This filter membrane only allows lipoaspirate tissue or cells that are smaller than the cutoff diameter to pass through. In still another alternative embodiment, the optional filter module is located upstream of the microfluidic device (e.g., upstream of the inlet to the microfluidic device but downstream with respect to the syringe).
In another embodiment, a method of processing a lipoaspirate sample includes mechanically processing the lipoaspirate sample to generate nanofat. The nanofat is then input into a microfluidic device comprising a plurality of serially arranged stages comprising one or more microfluidic channels having a plurality of expansion and constriction regions extending along the length of the one or more microfluidic channels, wherein each subsequent stage of the plurality has an increasing number of microfluidic channels of decreasing dimensions. The nanofat is flowed through the plurality of serially arranged stages in a plurality of cycles to generate sheared nanofat. The sheared nanofat is then collected after flowing through the plurality of serially arranged stages.
In another embodiment, a method of transforming fat cells from a subject includes obtaining a lipoaspirate sample from the subject containing the fat cells and removing connective tissue from the lipoaspirate sample using filtering or mechanical processing. The filtered lipoaspirate is then input into a microfluidic device comprising a plurality of serially arranged stages comprising one or more microfluidic channels having a plurality of expansion and constriction regions extending along the length of the one or more microfluidic channels, wherein each subsequent stage of the plurality has an increasing number of microfluidic channels of decreasing dimensions. The lipoaspirate is flowed through the plurality of serially arranged stages in a plurality of cycles to generate sheared lipoaspirate. The sheared lipoaspirate is then collected after flowing through the plurality of serially arranged stages.
In another embodiment, a method of transforming fat cells from a subject includes mechanically processing a lipoaspirate sample obtained from the subject sample to generate nanofat and inputting the nanofat into a microfluidic device comprising a plurality of serially arranged stages comprising one or more microfluidic channels having a plurality of expansion and constriction regions extending along the length of the one or more microfluidic channels, wherein each subsequent stage of the plurality has an increasing number of microfluidic channels of decreasing dimensions. The nanofat is flowed through the plurality of serially arranged stages in a plurality of cycles to generate sheared nanofat. The sheared nanofat is then collected after flowing through the plurality of serially arranged stages.
The innovative microfluidic-based method can be used to reproduce, with better results and reliability, the shear force environment of nanofat shearing. The microfluidic device enables, for example, an automated and consistent method of mechanical stress processing which has the potential to be used in the clinic to enhance fat grafting procedures among other autologous therapies. The microfluidic device allows for well-defined and enhanced fluid shear stresses to be applied to lipoaspirate samples, leading to stronger activation and/or enrichment of stem cell populations. Integration of the optional filter module will also result in a single platform in which SVF can be harvested, processed, and the resulting sample administered directly to a patient without further manipulation. This will be critical for clinical applications. It can be adapted to fit within a larger device comprising a series of the microfluidic devices allowing for delivery of a sufficient volume of regenerative multipotent cells. In some embodiments, the device may be divided into one section that cleans, filters, and delivers material for traditional fat grafting, while the other section utilizes this microfluidic platform to deliver the concentration of regenerative cells. Both may be combined for cell assisted lipotransfer or they may be used separately for various indications.
In the embodiment illustrated in
In an alternative embodiment, the second pump 106 may be omitted and the output that exits the outlet 14 may be recirculated back to the inlet 12 to complete additional passes or cycles through the microfluidic device 10. For example, a peristaltic-type pump could recirculate the nanofat 110 through the microfluidic device 10 for multiple cycles.
In another alternative embodiment, the filter module 120 is located upstream with respect to the microfluidic device 10. For example, the filter module 120 would be located downstream of the syringe 100 but upstream of the microfluidic device 10. In one particular embodiment, the filter module 120 may include a filter medium or filtering structure that is used to remove connective tissue or larger-sized tissue matter. The filter medium or filtering structure may include mechanical obstructions or the like that disrupt the lipoaspirate sample into smaller-sized clusters of cells or cell populations while retaining the bulky connective tissue (e.g., collagen). In this particular example, rather than run nanofat 110 through the microfluidic device 10, the filtered lipoaspirate may be directly run through the microfluidic device 10. In this embodiment, with reference to
The microfluidic device 10 is preferably made from multiple layers which are laminated together to form the completed microfluidic device 10. For example, hard plastic such as polyethylene terephthalate (PET) can be laser cut into desired patterns and then aligned in a stack and fused together using intermediate adhesive layer(s) and pressure lamination. The hard plastic format is more robust than alternatives produced using photolithography and polydimethyl siloxane (PDMS). In a separate embodiment, the device may be made as a single layer using a 3D printer.
Referring back to
In one embodiment, the expansion regions 20 and constriction regions 21 are a continuous expansion and constriction of the channel width. This will modulate fluid velocity, actively mixing the sample and generating shear forces across tissue and cell aggregates. The expansion regions 20 and constriction regions 21 are connected by smooth curved lines, resulting in relatively gradual velocity changes to avoid that turbulent mixing and recirculating flows. In one embodiment, the maximum width in the expansion region is 3-fold greater than the minimum width in the constriction, and this ratio is maintained throughout the microfluidic device 10. In this embodiment, the constriction regions are separated by a distance equal to the expansion region width. This results in an increase in the number of constrictions per channel through the device 10. While the expansion regions 20 and the constriction regions 21 are oriented along with width of the microfluidic device 10 these could also be oriented along the height direction.
The second stage 16B is connected to the downstream end of the first stage 16A at the end of microfluidic channel 18. The second stage 16B may be located in a different layer of the microfluidic device 10 than the first stage 16A whereby the second stage 16B is connected to the first stage 16A using a vias 22. The second stage 16B includes a plurality of microfluidic channels 24 with each microfluidic channel 24 having a plurality of expansion regions 20 and constriction regions 21 formed therein. In addition, the dimensions of the microfluidic channels 24 within the second stage 16B are narrowed as compared to the microfluidic channel 18 of the first stage 16A. In one aspect of the invention, the second stage 16B includes two microfluidic channels 24 wherein the width of each channel 24 is reduced by a factor of about x/2 where x represents the minimum width of the microfluidic channel 18 of the first stage 16A. The height of the microfluidic channels 18, 24 remains the same. The height may vary but is generally within the range of about 200 to about 500 μm.
Still referring to
A fourth stage 16D is connected to the end of the third stage 16C. The fourth stage 16D includes eight microfluidic channels 30 with pairs of microfluidic channels 30 connecting to the downstream end of the microfluidic channels 26. The interface between the end of the third stage 16C and the beginning of the fourth stage 16D may be accomplished through vias 32. In one aspect of the invention, the fourth stage 16D includes eight microfluidic channels 30 wherein the minimum width of each microfluidic channel 30 is reduced by a factor of about x/8 where x represents the minimum width of the microfluidic channel 18 of the first stage 16A. Thus, if the minimum width of the first stage 16A is 2 mm then the minimum width of the fourth and final stage 16D is 250 μm (2 mm to 1 mm to 500 μm to 250 μm). If the minimum width of the first stage 16A is 4 mm then the minimum width of the fourth and final stage 16D is 500 μm (4 mm to 2 mm to 1 mm to 500 μm). The multiple acrylic layers of the microfluidic device 10 may be secured together via fasteners such as screws or the like. Alternatively, the various layers may be bonded to one another.
While the microfluidic device 10 described herein has four stages 16A, 16B, 16C, 16D fewer or more stages can be used. Further, while each successive set of microfluidic channels located in a downstream stage is described as having a minimum width that is about one-half the minimum width of the immediately upstream microfluidic channels, other fractions are contemplated (e.g., ¼, ⅓, etc.). In addition, in the embodiment illustrated in
In the mechanical processing operation 210, the lipoaspirate is converted to nanofat 110. Mechanical processing may involve vigorously passing the lipoaspirate back-and-forth between two connected syringes (connected via Luer connector or tubing). Mechanical processing may also include, in addition to or as an alternative to syringe-to-syringe processing, straining or even filtration of the lipoaspirate to remove connective tissue. Next, as seen in operation 220, the nanofat 110 is then input into the microfluidic device 10 described herein that has the plurality of stages that impart shear stress on the sample using the plurality of expansion regions 20 and contraction regions 21.
In the example illustrated in
For experiments described herein, two versions of the microfluidic device 10 were created. A first version is referred to as “v2” in which case the fourth or final stage has a constriction width of 250 μm. A second version of the microfluidic device 10 is referred to as “v4” and used a fourth or final stage with a constriction width of 500 μm. The height for both versions of the device was 300 μm.
Experiments were conducted on standard lipoaspirate (i.e., macrofat) as well as nanofat prepared by passing macrofat between two syringes in a repeated manner. Lipoaspriate samples are from human subjects undergoing routine liposuctions procedures at UCI hospital (IRB #2015-2181) and washed thoroughly with phosphate buffered saline (PBS) prior to processing. For a control, macrofat was processed in the traditional manner using collagenase. Nanofat-derived stromal vascular fraction (SVF) is known to contain significantly reduced proportion of viable cells compared to standard lipoaspirate. Conversely, nanofat-derived SVF is known to have a greater proportion of mesenchymal stem cells (MSCs), adipose derived stem cells (ADSCs), endothelial progenitor cells (EPCs), and Muse cells. It was postulated that the amount of stress that is applied to cells directly correlates with stem-like properties.
Experiments were conducted on fat (standard lipoaspirate) that was obtained from a single patient that was washed with PBS until golden in color. Nanofat was prepared by passing standard lipoaspirate between two syringes at a rate of 20 ml/second. Once emulsified, the tissue was passed through a standard kitchen strainer. The filtrate was collected and one portion set aside as a positive control, while two samples were passed through each microfluidic device for thirty (30) passes at 12.5 ml/min.
The control and emulsified lipoaspirate were then processed for SVF. A 0.1% enzymatic digestion solution was prepared by combining type I collagenase with PBS which was then sterilized using a 0.22 μm vacuum filter. A 1:1 volume of collagenase solution to lipoaspirate was incubated in a water bath at 37° C. for 30 minutes, swirling intermittently. An equal volume of control medium (Dulbecco's Modified Eagle Medium, 10% fetal bovine serum, 500 IU Penicillin, 500 μg Streptomycin) was then added to neutralize enzymatic activity and the mixture was allowed to separate for at least 10 minutes. The liquid infranatant layer containing the SVF was isolated, filtered through a 100 μm cell strainer, and centrifuged at 1800 rpm for 8 minutes. Each pellet was then resuspended in red blood cell lysis buffer (15.5 mM NH4Cl, 1 mM KHCO3, and 0.01 mM EDTA) for 5 minutes to minimize erythrocyte contamination. After the addition of 5 mL control medium, the suspensions were centrifuged one final time. The aqueous portions were removed by aspiration after each centrifugation step. The resulting pellets were then resuspended in control media and subjected to staining and analysis. Macrofat is standard lipoaspirate (control group) that was digested with collagenase for SVF isolation as described above.
A variety of research indicates that CD34 serves as a universal marker for stem cell activity. The presence of this marker combined with the absence of CD45 denotes a broad definition for mesenchymal sternness. Various other markers including CD13, CD73 and CD146 are associated with multipotentiality of the mesenchyme. The presence or absence of CD31 allows for the analysis of endothelial progenitor cells versus other constituents of the stromal vascular fraction. DPP4+ (CD26)/CD55+ cells have recently been identified as the crucial stem cell subtype associated with diabetic wound healing. Finally, the presence of both markers SSEA-3 combined with CD13 connote a pluripotent stem cell population.
All the recovered cell pellets were counted via LunaSTEM automated cell counter followed by the absolute cell count function using a MACSQuant flow cytometer. Nanofat groups resulted in a ˜4-fold decrease in cell count (
While embodiments of the present invention have been shown and described, various modifications may be made without departing from the scope of the present invention. The invention, therefore, should not be limited except to the following claims and their equivalents.
This Application claims priority to U.S. Provisional Patent Application No. 62/289,883 filed on Feb. 1, 2016, which is hereby incorporated by reference in its entirety. Priority is claimed pursuant to 35 U.S.C. § 119 and any other applicable statute.
Number | Name | Date | Kind |
---|---|---|---|
4883763 | Holen et al. | Nov 1989 | A |
8080380 | Chee | Dec 2011 | B2 |
20020142470 | Clarke et al. | Oct 2002 | A1 |
20040137607 | Tanaami et al. | Jul 2004 | A1 |
20050138567 | Smith et al. | Jun 2005 | A1 |
20060223178 | Barber | Oct 2006 | A1 |
20070025876 | Nishijima et al. | Feb 2007 | A1 |
20070025930 | Rico-Lattes et al. | Feb 2007 | A1 |
20070026416 | Fuchs | Feb 2007 | A1 |
20070026426 | Fuchs | Feb 2007 | A1 |
20070092876 | Xu | Apr 2007 | A1 |
20090014360 | Toner et al. | Jan 2009 | A1 |
20090098541 | Southern | Apr 2009 | A1 |
20090155877 | Illiescu | Jun 2009 | A1 |
20100081189 | Zantl et al. | Apr 2010 | A1 |
20100190265 | Dufva et al. | Jul 2010 | A1 |
20110085950 | Lee et al. | Apr 2011 | A1 |
20120100521 | Soper | Apr 2012 | A1 |
20130149724 | Chander | Jun 2013 | A1 |
20130295598 | Marx et al. | Nov 2013 | A1 |
20140057311 | Kamm et al. | Feb 2014 | A1 |
20140120537 | Chang | May 2014 | A1 |
20140248621 | Collins | Sep 2014 | A1 |
20140377866 | Haun et al. | Dec 2014 | A1 |
20150231244 | Chi et al. | Aug 2015 | A1 |
20150285785 | Hahn | Oct 2015 | A1 |
20150285786 | Hahn et al. | Oct 2015 | A1 |
20150377861 | Pant et al. | Dec 2015 | A1 |
20160047735 | Grisham et al. | Feb 2016 | A1 |
20170131187 | Haun et al. | May 2017 | A1 |
20180106805 | Allen | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
2013216683 | Sep 2007 | AU |
2609361 | Nov 2006 | CA |
2327789 | Sep 2007 | CA |
2760574 | Nov 2010 | CA |
2799901 | Nov 2011 | CA |
2924883 | Mar 2015 | CA |
162188 | Jan 2016 | CA |
2963468 | Apr 2016 | CA |
2572113 | Apr 2017 | CA |
2609361 | Nov 2017 | CA |
101443023 | May 2009 | CN |
106434542 | Jan 2010 | CN |
201389496 | Jan 2010 | CN |
102458302 | May 2012 | CN |
102002478 | Jan 2013 | CN |
102861105 | Jan 2013 | CN |
103038333 | Apr 2013 | CN |
104630139 | May 2015 | CN |
105934155 | Sep 2016 | CN |
106834121 | Jun 2017 | CN |
1778834 | Nov 2010 | DK |
1778833 | Jun 2011 | DK |
1885382 | Jun 2011 | DK |
1599575 | Jan 2012 | DK |
1778834 | Jan 2012 | DK |
1921133 | Aug 2015 | DK |
1638507 | Jun 2017 | DK |
1670315 | Aug 2017 | DK |
2571975 | Oct 2017 | DK |
3046417 | Oct 2017 | DK |
2145951 | Jan 2010 | EP |
2145952 | Jan 2010 | EP |
1778833 | Mar 2011 | EP |
1885382 | Mar 2011 | EP |
2332555 | Jun 2011 | EP |
2343360 | Jul 2011 | EP |
2305276 | Sep 2011 | EP |
2308963 | Sep 2011 | EP |
2371943 | Oct 2011 | EP |
1778834 | Nov 2011 | EP |
1599575 | Mar 2012 | EP |
2348103 | Jul 2012 | EP |
2571975 | Mar 2013 | EP |
1743021 | Mar 2014 | EP |
1778293 | Apr 2015 | EP |
1776126 | May 2015 | EP |
1921133 | May 2015 | EP |
2980206 | Feb 2016 | EP |
2617427 | Aug 2016 | EP |
3046417 | Sep 2016 | EP |
3106511 | Dec 2016 | EP |
2422622 | Jan 2017 | EP |
1638507 | Mar 2017 | EP |
1670315 | Apr 2017 | EP |
2571975 | Jul 2017 | EP |
3046417 | Jul 2017 | EP |
2574663 | Aug 2017 | EP |
2380970 | Dec 2017 | EP |
3106512 | Mar 2018 | EP |
3299451 | Mar 2018 | EP |
2465923 | Apr 2018 | EP |
2364957 | Sep 2011 | ES |
2364689 | Feb 2012 | ES |
2373551 | Feb 2012 | ES |
2545385 | Sep 2015 | ES |
2633604 | Sep 2017 | ES |
2641547 | Nov 2017 | ES |
2649387 | Jan 2018 | ES |
1078009 | Jun 2011 | HK |
1096424 | Feb 2013 | HK |
1165261 | Aug 2015 | HK |
P20171471 | Nov 2017 | HR |
2008278821 | Nov 2008 | JP |
2008278822 | Nov 2008 | JP |
2009-75067 | Apr 2009 | JP |
2009189280 | Aug 2009 | JP |
2009189281 | Aug 2009 | JP |
2009189282 | Aug 2009 | JP |
2009269930 | Nov 2009 | JP |
2010032444 | Feb 2010 | JP |
2010043876 | Feb 2010 | JP |
2010075066 | Apr 2010 | JP |
2010075114 | Apr 2010 | JP |
2010095531 | Apr 2010 | JP |
2010127620 | Jun 2010 | JP |
2010127708 | Jun 2010 | JP |
2010148450 | Jul 2010 | JP |
2010148451 | Jul 2010 | JP |
2011010615 | Jan 2011 | JP |
2011010616 | Jan 2011 | JP |
2012051923 | Mar 2012 | JP |
2012075439 | Apr 2012 | JP |
2012149088 | Aug 2012 | JP |
2014031389 | Feb 2014 | JP |
05960689 | Aug 2016 | JP |
2016136956 | Aug 2016 | JP |
06208787 | Oct 2017 | JP |
2018030815 | Mar 2018 | JP |
2005109941 | Nov 2005 | KR |
2006025180 | Mar 2006 | KR |
2006030861 | Apr 2006 | KR |
2007002058 | Jan 2007 | KR |
2007017974 | Feb 2007 | KR |
2007038538 | Apr 2007 | KR |
2007089254 | Aug 2007 | KR |
779812 | Nov 2007 | KR |
2008017389 | Feb 2008 | KR |
811995 | Mar 2008 | KR |
2008103611 | Nov 2008 | KR |
930139 | Dec 2009 | KR |
2010029272 | Mar 2010 | KR |
1083454 | Nov 2011 | KR |
2012003961 | Jan 2012 | KR |
2012020143 | Mar 2012 | KR |
1127305 | Apr 2012 | KR |
2012038534 | Apr 2012 | KR |
1145508 | May 2012 | KR |
1150666 | Jul 2012 | KR |
1197909 | Nov 2012 | KR |
2013038412 | Apr 2013 | KR |
1278437 | Jun 2013 | KR |
1310578 | Sep 2013 | KR |
1400544 | May 2014 | KR |
2016055827 | May 2016 | KR |
2017115296 | Oct 2017 | KR |
2017115377 | Oct 2017 | KR |
2011011402 | Feb 2012 | MX |
2016003127 | Oct 2016 | MX |
WO2003024215 | Mar 2003 | WO |
WO2003053346 | Jul 2003 | WO |
WO2003053362 | Jul 2003 | WO |
WO2005012480 | Feb 2005 | WO |
WO2006014156 | Feb 2006 | WO |
WO20060175980 | Jul 2006 | WO |
WO2006069349 | Sep 2006 | WO |
WO2006039129 | Dec 2006 | WO |
WO2007061530 | May 2007 | WO |
WO2007139551 | Dec 2007 | WO |
WO2008060466 | Aug 2008 | WO |
WO2008013863 | Oct 2008 | WO |
WO2008140046 | Nov 2008 | WO |
WO2006112941 | Dec 2008 | WO |
WO2006127007 | Apr 2009 | WO |
WO2009055610 | Apr 2009 | WO |
WO2009076548 | Jun 2009 | WO |
WO2008140044 | Aug 2009 | WO |
WO2009101910 | Aug 2009 | WO |
WO2010021993 | Feb 2010 | WO |
WO2010035709 | Apr 2010 | WO |
WO2010073808 | Jul 2010 | WO |
WO2010124235 | Oct 2010 | WO |
WO2010127310 | Nov 2010 | WO |
WO2011145075 | Nov 2011 | WO |
2012139209 | Oct 2012 | WO |
WO2013144883 | Oct 2013 | WO |
WO2013144883 | Nov 2013 | WO |
WO2014016750 | Jan 2014 | WO |
WO2014064642 | May 2014 | WO |
WO 2014130391 | Aug 2014 | WO |
WO2015042182 | Mar 2015 | WO |
WO 2015127126 | Aug 2015 | WO |
WO2015120388 | Aug 2015 | WO |
WO2015140737 | Sep 2015 | WO |
WO2016007434 | Jan 2016 | WO |
WO2016054592 | Apr 2016 | WO |
WO2017100328 | Jun 2017 | WO |
WO2017115289 | Jul 2017 | WO |
WO2017125159 | Jul 2017 | WO |
WO2017195156 | Nov 2017 | WO |
Entry |
---|
Bassaneze et al., “Shear Stress Induces Nitric Oxide-Mediated Vascular Endothelial Growth Factor Production in Human Adipose Tissue Mesenchymal Stem Cells”, Stem Cells and Development, 2010, vol. 19, No. 3, pp. 371-378. (Year: 2010). |
Topcu et al., “Increasing the Viability of Fat Grafts by vascular Endothelial Growth Factor”, Arch Facial Plast Surg, 2012, 14(4), pp. 270-276. (Year: 2012). |
Alharbi et al., “Conventional vs. micro-fat harvesting: How fat harvesting technique affects tissue-engineering approaches using adipose tissue-derived stem/stromal cells”, Journal of Plastic, Reconstructive & Aesthetic Surgery (2013), vol. 66, pp. 1271-1278. (Year: 2013). |
Office Action dated May 8, 2018 in U.S. Appl. No. 15/413,201, (20pages). |
Office Action dated Sep. 6, 2017 in U.S. Appl. No. 15/413,201, (12pages). |
Restriction Requirement dated Jun. 1, 2017 in U.S. Appl. No. 15/413,201, (5pages). |
Office Action dated Feb. 23, 2017 in U.S. Appl. No. 15/413,201, (10pages). |
Kim, M. Y. et al., Microfabrication of High-Resolution Porous Membranes for Cell Culture, J. Memb. Sci. 452, 460-469 (2014). |
MACS Miltenyi Biotec, gentleMACSTM Dissociator, The gentle way of automated tissue dissociation, gentlemacs.com (2pages), 2010. |
Banyard, Derk A. et al., Phenotypic Analysis of Stromal Vascular Fraction after Mechanical Shear Reveals Stress-Induced Progenitor Populations, Pastic and Reconstructive Surger, Aug. 2016, vol. 138, No. 2, Shear Stress Progenitor Morphogenesis, www.PRSJournal.com, 237e-247e. |
Bianchi, Francesca et al., A New Nonenzymatic Method and Device to Obtain a Fat Tissue Derivative Highly Enriched in Pericyte-Like Elements by Mild Mechanical Forces From Human Lipoaspirates, Cell Transplantation, vol. 22, pp. 2063-2077, 2013. |
Conde-Green, Alexandra et al., Effects of Centrifugation on Cell Composition and Viability of Aspirated Adipose Tissue Processed for Transplantation, Aesthetic Surgery Journal, 30(2) 249-255 (2009). |
Conde-Green, Alexandra et al., Influence of decantation, washing and centrifugation on adipocyte and mesenchymal stem cell content of aspirated adipose tissue: A comparative study, Journal of Plastic, Reconstructive & Aesthetic Surgery (2010) 63, 1375-1381. |
Heneidi, Saleh et al., Awakened by Cellular Stress: Isolation and Characterization of a Novel Population of Pluripotent Stem Cells Derived from Human Adipose Tissue, PLOS ONE, www.plosone.org, Jun. 2013, vol. 8, Issue 6, e64752 (14pages). |
Tonnard, Patrick et al., Nanofat Grafting: Basic Research and Clinical Applications, Plastic and Reconstructive Surgery, Oct. 2013, vol. 132, No. 4, Nanofat Grafting, www.PRSJournal.com, 2013. |
Office Action dated Mar. 26, 2019 in U.S. Appl. No. 15/413,201, (21pages). |
Interview Summary dated Jul. 14, 2019 in U.S. Appl. No. 15/413,201, (3pages). |
PCT International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) for PCT/US2017/036429, Applicant: The Regents of the University of California, Form PCT/IB/326 and 373, dated Dec. 20, 2018 (14pages). |
Notice of Preliminary Rejection (non-final) dated Mar. 21, 2019 for Korean Patent Application No. 10-2019-7000183, Applicant: The Regents of the University of California (19pages). |
Office Action dated Feb. 8, 2019 in U.S. Appl. No. 16/101,254, (46pages). |
Office Action dated Oct. 31. 2018 in U.S. Appl. No. 16/101,254, (32pages). |
Amendment and Response dated Jan. 29, 2019 in U.S. Appl. No. 16/101,254, (19pages). |
Final Office Action dated Feb. 8, 2019 in U.S. Appl. No. 16/101,254, (46pages). |
Request for Continued Examination and Response dated Apr. 18, 2019 in U.S. Appl. No. 16/101,254, (19pages). |
Response to Office Action dated Jul. 26, 2019 in U.S. Appl. No. 15/413,201, (19pages). |
Adams, Andre A. et al., Highly Efficient Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using Polymer-Based Microfluidics with an Integrated Conductivity Sensor, J Am Chem Soc., Jul. 9, 2008; 130(27): 8633-8641. doi:10.1021/ja8015022. |
Final Office Action dated Sep. 5, 2018 in U.S. Appl. No. 15/413,201, (18 pages). |
Office Action dated Mar. 26, 2019 in U.S. Appl. No. 15/413,201, (17 pages). |
Final Office Action dated Aug. 7, 2019 in U.S. Appl. No. 15/413,201, (52 pages). |
Notice of Allowance and Issue Fee dated Feb. 7, 2020 in U.S. Appl. No. 15/413,201, (18 pages). |
Number | Date | Country | |
---|---|---|---|
62289883 | Feb 2016 | US |